Background-Low serum levels of the amino acid derivative, homoarginine, have been associated with increased risk of total and cardiovascular mortality. Homoarginine deficiency may be related to renal and heart diseases, but the pathophysiologic role of homoarginine and the genetic regulation of its serum levels are largely unknown. Methods and Results-In 3041 patients of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study referred for coronary angiography and 2102 participants of the Young Finns Study (YFS), we performed a genome-wide association study to identify genomic loci associated with homoarginine serum levels and tested for associations of identified singlenucleotide polymorphisms with mortality in LURIC. We found genome-wide significant associations with homoarginine serum levels on chromosome 2 at the carbamoyl phosphate synthetase I locus, on chromosome 5 at the alanine-glyoxylate aminotransferase 2 locus, and on chromosome 15 at the glycine amidinotransferase locus, as well as a suggestive association on chromosome 6 at the Homo sapiens mediator complex subunit 23 gene/arginase I locus. All loci harbor enzymes located in the mitochondrium are involved in arginine metabolism. The strongest association was observed for rs1153858 at the glycine amidinotransferase locus with a P value of 1.25E-45 in the combined analysis and has been replicated in both the Die Deutsche Diabetes Dialyse Studie (4D study) and the Graz Endocrine Causes of Hypertension (GECOH) study. Conclusions-In our genome-wide association study, we identified 3 chromosomal regions significantly associated with serum homoarginine and another region with suggestive association, providing novel insights into the genetic regulation of homoarginine. (Circ Cardiovasc Genet. 2013;6:505-513.)
H omoarginine, a cationic amino acid, has been suggested previously to exert protective cardiovascular effects, putatively mediated by regulating the synthesis of the endothelial-derived relaxing factor, nitric oxide. 1, 2 Data from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study have shown that low homoarginine is a significant and independent risk factor for all-cause and cardiovascular mortality. 3 These findings among patients referred for coronary angiography were replicated in a cohort of dialysis patients with type 2 diabetes mellitus participating in the Die Deutsche Diabetes Dialyse Studie (4D study). 3 More detailed analyses on specific causes of death revealed an association of low homoarginine levels with fatal stroke 4 and sudden cardiac death, 5 as well as a positive correlation of homoarginine with angiographic left ventricular ejection fraction and an inverse correlation with N-terminal pro-B-type natriuretic peptide, 6 which might point to previously unknown pathophysiologic processes that could be relevant for the diagnosis and treatment of life-threatening heart and kidney diseases. [1] [2] [3] [4] [5] [6] Clinical Perspective on p 513
The current understanding of homoarginine metabolism is, however, in its infancy. Previous studies suggest that homoarginine is mainly derived from the kidney and may thus be associated with renal function. 7, 8 Beyond this, we recently found an association between homoarginine and bone metabolism, 9, 10 and a recent report found a key role of the enzyme glycine amidinotransferase (GATM) in homoarginine synthesis. 11 l-Lysine can serve as a precursor for homoarginine synthesis, but detailed enzymatic key reactions determining homoarginine serum levels are largely unknown. 7, 8 We performed a genome-wide association study (GWAS) to identify genes that are involved in the regulation of homoarginine serum levels. Our study was performed on 3041 patients from the LURIC study, who were followed up for ≈10 years with respect to fatal events and in 2102 participants of the Young Finns Study (YFS). We further aimed to replicate identified genetic polymorphisms in 1244 hemodialysis patients with type 2 diabetes mellitus recruited from the 4D study 12 and 230 patients of the Graz Endocrine Causes of Hypertension (GECOH) study. 13
Methods

Study Populations
LURIC Study
The LURIC study consists of 3316 white patients hospitalized for coronary angiography between 1997 and 2000 at a tertiary care center in Southwestern Germany. 14 Clinical indications for angiography were chest pain or a positive noninvasive stress test suggestive of myocardial ischemia. To limit clinical heterogeneity, individuals experiencing acute illnesses other than acute coronary syndrome, chronic noncardiac diseases, and a history of malignancy within the 5 past years were excluded. The study was approved by the ethics committee at the Ärztekammer Rheinland-Pfalz and was conducted in accordance with the Declaration of Helsinki. Informed written consent was obtained from all participants. In 3041 LURIC participants, genotypes, homoarginine levels, and all necessary covariates were available.
Cardiovascular Risk in YFS
In brief, the YFS cohort is a Finnish longitudinal population study sample on the evolution of cardiovascular risk factors from childhood to adulthood. 15 In the present study, we used the variables measured in 2001. For these subjects, genotyping was performed in 2009 using a custom-built Illumina Human 670k BeadChip at the Welcome Trust Sanger Institute. In 2102 subjects, genotype, risks factors, and phenotype data were complete, and they formed the present study population. This study was conducted according to the guidelines of the Declaration of Helsinki, and the study protocol was approved by local ethics committees. All participants gave their informed consent.
Tampere Vascular Study
Vascular sample series from femoral arteries, carotid arteries, and abdominal aortas were obtained during open vascular procedures between 2005 and 2008. The study has been approved by the Ethics Committee of Tampere University Hospital. All clinical investigations were conducted according to the Declaration of Helsinki. Tampere Vascular Study (TVS) whole blood and monocyte collections were performed in 2008, the angiographically verified patient samples to new TVS study were preselected from a larger population-based study, 16 and 55 individuals with angiographically verified coronary artery disease and 45 without were selected. The participant pool comprises patients who have undergone an exercise-stress test at Tampere University Hospital. A description of the studies used for replication is supplied in the online-only Data Supplement.
Clinical Definitions
In LURIC, coronary artery disease (CAD) has been defined angiographically using the maximum luminal narrowing estimated by visual analysis. CAD was defined as the presence of a visible luminal narrowing (>20% stenosis) in ≥1 of 15 coronary segments according to a classification of the American Heart Association. Diabetes mellitus has been defined according to American Diabetes Association (ADA) 2010 guidelines as increased fasting (>126 mg/dL), postchallenge (2 hours after the 75 g glucose load >200 mg/dL) glucose, elevated glycated hemoglobin (>6.5%), and history of diabetes mellitus. Hypertension was defined as a systolic and diastolic blood pressures >140 and >90 mm Hg, respectively, or a significant history of hypertension.
Laboratory Procedures
For LURIC patients, fasting blood samples were obtained by venipuncture in the early morning. Blood glucose, cholesterol, and triglycerides were measured by standard laboratory procedures as described previously. 14 High-density lipoprotein cholesterol was measured after separating lipoproteins with a combined ultracentrifugation-precipitation method. 14 Genomic DNA was prepared from EDTA-anticoagulated peripheral blood using a common salting-out procedure. Total homocysteine concentration in EDTA plasma was determined by high-performance liquid chromatography (Waters millennium chromatography with fluorescence detector 470). Arginine was measured in serum samples with a conventional amino acid analysis technique, involving separation of amino acids by ion exchange chromatography followed by postcolumn continuous reaction with ninhydrin. 17 Creatine was determined in serum by liquid chromatography tandem mass spectrometry. 18 For YFS subjects, venous blood samples were drawn after an overnight fast. Standard enzymatic methods were used for serum total cholesterol, triglycerides, and high-density lipoprotein cholesterol.
Homoarginine was measured in all studies in serum stored at −80°C by a reversed phase high-performance liquid chromatography at the Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz. 19, 20 Intraday coefficients of variation at different concentrations (mean levels) were 4.7% (1.21 μmol/L) and 2.2% (3.53 μmol/L), and between-day coefficients of variation were 7.9% (1.25 μmol/L) and 6.8% (3.66 μmol/L).
Genotyping and Quality Control
In LURIC, genotyping was done using the Affymetrix Human SNP Array 6.0 at the LURIC study facility, whereas in YFS, genotyping was done using a custom-built Illumina Human 670k BeadChip at the Welcome Trust Sanger Institute ( Table I in the online-only Data  Supplement) . Genotype imputation in both studies was performed using MACH 1.0 21, 22 and HapMap II CEU (release 22, National Center for Biotechnology Information build 36, dbSNP 126) samples as a reference. After imputation, 2 543 887 Single-nucleotide polymorphisms (SNPs) were available. SNPs with a squared correlation of ≥0.3 between imputed and true genotypes were considered well imputed. For TVS samples, genotyping was done using the Illumina HumanHap660W-Quad BeadChip (Illumina, Inc, San Diego, CA) according to the manufacturer's recommendation.
Expression Analyses
The expression levels of cells from whole blood, monocytes, and artery cells were analyzed with an Illumina HumanHT-12 v3 Expression BeadChip (Illumina).The BeadChips were scanned with the Illumina iScan system. Raw intensity data were exported using the Illumina GenomeStudio software. Further data processing was conducted by means of R language and appropriate Bioconductor modules. A more detailed description is provided in the online-only Data Supplement.
Statistical Analyses
For the main GWAS analysis, we did linear regression on homoarginine serum levels with adjustment for principle components to control for population stratification. As the distribution of homoarginine levels was a bit skewed to the left, we additionally performed an analysis based on residuals that were obtained using linear regression analysis in which homoarginine levels were adjusted for sex, age, and body mass index (relevant covariates that were identified using stepAIC function in R software), as well as principal components to control for population stratification, and inverse normal transformation was used to obtain a normal distribution.
SNPs were evaluated for association with homoarginine using linear regression analyses using the software QUICKTEST (http://toby. freeshell.org/software/quicktest.shtml) in LURIC and ProbABEL 23 in YFS. QQ and Manhattan plots were drawn for the analysis of the results. Regional plots were drawn using Locuszoom. 24 The P value for genomewide significance was set at P<5×10 −8 , which corresponds to an α of 0.05 with a Bonferroni correction for 1 million tests. Meta-analysis of both studies was done using a fixed-effect, effective sample-weighted Z-score meta-analysis method, as implemented in the software METAL. 25 Further statistical analyses were performed using the R statistical software version 2.15.0 (http://www.r-project.org) and IBM SPSS Statistics version 20.0 (IBM Corportion).
Expression quantitative trait locus analysis with lead SNPs was performed with the Genevar software using a window of ±1 Mb centered on the SNP. 26 The strength of the relationship between alleles and gene expression intensities was estimated using Spearman rank correlation and reported as nominal P values.
Results
Study Description
For the current analysis, 3041 samples from LURIC and 2102 samples from YFS have been included, making a total of 5143 samples. Basic characteristics for both studies are shown in Table 1 . LURIC participants were on average significantly older than YFS participants with a much higher percentage of men, higher body mass index, higher blood pressure, lower high-density lipoprotein cholesterol, and higher triglycerides. Although in LURIC ≈80% of patients had CAD and ≈40% had diabetes mellitus, there were no known patients with CAD in the YFS, and only 0.6% had diabetes mellitus. Homoarginine levels were higher in LURIC than in YFS.
Association Analyses
A Manhattan plot of the combined meta-analysis is shown in Figure 1 These SNPs are located on chromosome 2 at the CPS1 locus (carbamoyl phosphate synthetase I: EC 6.3.4.16), on chromosome 5 at the AGXT2 locus (alanine-glyoxylate aminotransferase: EC 2.6.1.44), and on chromosome 15 at the GATM locus (GATM: EC 2.1.4.1). We also identified another region on chromosome 6 at the MED23/ARG1 locus (Homo sapiens mediator complex subunit 23 gene/arginase I), which we considered as a suggestive association (P value of 1.80×10 -7 for the lead SNP rs17060430). Regional plots of the 3 genome-wide significant regions and the putative region on chromosome 6 are shown in Figures 2 to 5. The strongest association with homoarginine in the joined meta-analysis was observed for rs1153858 with a P value of 1.25×10 -45 and a decrease in homoarginine serum concentration of 0.271 and 0.253 µmol/L per C allele in LURIC and YFS, respectively ( Table 2 ). rs1153858 explained 3.3%, 5.3%, 2.0%, and 4.8% of the variance of homoarginine in LURIC, YFS, 4D, and GECOH, respectively.
We further sought to replicate the associations in 2 different cohorts, the 4D study and the GECOH study. In both studies, the association of rs1153858 with homoarginine could be replicated (P<0.001 in 4D; P=0.001 in GECOH; Table 3 ), whereas there was no association of rs37370 at the AGXT2 locus. In the 4D study, we also were able to show the association of rs1047891 at the CPS1 locus with homoarginine (P=0.001; Table 3 ).
Analysis of inverse normal transformed residuals of a regression model adjusted for sex, age, and body mass, as well as principal components, gave similar results like the analysis of the untransformed phenotype with P values of most SNPs even being a bit lower ( Table V in 
Expression Quantitative Trait Locus Expression Analysis
We examined the association of the lead SNPs in the 3 identified loci with gene expression in transcriptomic profiles of 3 different tissues of the TVS. The major allele of rs1346268 at the GATM locus (r 2 =0.998 with rs1153858) was significantly associated with increased mRNA levels of GATM and nearby genes in cells from the arterial plaque and whole blood, as well as in monocytes ( Figure 6 ). For the CPS1 locus and the AGXT2 locus, no association of the lead SNPs with gene expression could be detected (data not shown).
Discussion
In our GWAS performed in 2 large cohorts of white patients, we identified sequence variants at 3 genomic loci as significant predictors of serum homoarginine levels. The strongest signal was observed on chromosome 15 at the GATM locus. GATM, also called l-arginine:GATM (AGAT; EC 2.1.4.1), plays a central role in energy metabolism by catalyzing the conversion of arginine and glycine to ornithine and guanidinoacetate. [27] [28] [29] Guanidinoacetate is subsequently converted to creatine, which serves as a buffer and an energy shuttle for phosphate-bound energy, particularly for ATP. Our results suggest that GATM is significantly involved in the metabolism of homoarginine, which confirms a recent report by Davids et al, 11 who found that homoarginine synthesis was undetectable in GATM-deficient lymphoblasts. When arginine is replaced by homoarginine as a substrate, the GATM reaction yields guanidinoacetate and lysine instead of ornithine. Lysine, in turn, can be converted to homoarginine again via a reverse reaction by GATM or alternatively via homocitrulline and homoargininosuccinate similar to the reactions taking place in the urea circle.
Allelic variants in the GATM gene have been implicated with arginine:glycine amidinotransferase deficiency (online Mendelian inheritance in man no. 612718), an autosomal recessive disorder characterized by developmental delay, mental retardation, and severe depletion of creatine/phosphocreatine in the brain. 30 GATM mRNA expression is highest in the kidney, which is thought to be the major site of homoarginine synthesis. 31 In addition, GATM is also expressed in other tissues, such as liver and brain, skeletal muscle, heart, lung, and salivary glands. 31 The lead SNP identified in our GWAS, rs1153858, is located ≈600 bp downstream of the GATM gene. It is in high linkage disequilibrium (r 2 =1) with a nonsynonymous coding variant, rs1288775 (P=8.52×10 -56 in meta-analysis), which codes the exchange of glutamine against histidine at position 110. However, both Poly-Phen2 32 and Sorting Intolerant From Tolerant (SIFT) 33 predict this exchange to be benign. eQTL expression analysis identified another SNP in linkage to rs1153858 (rs1346268, P=1.3×10 -55 in meta-analysis) that is associated with GATM mRNA levels in cells taken from artery and whole blood and in monocytes. The minor allele of rs1346268 was associated with lower levels of mRNA, whereas the minor allele of rs1153858 was associated with higher serum homoarginine.
A lookup in the ENCODE data using HaploReg 34 showed that rs1153858 changes a potential binding motif for the transcription factor paired box 1 (PAX-1), whereas rs1346268 changes an AIRE_2 motif. Several other potential binding motifs are reported in the same haploblock.
In line with the role of GATM in the synthesis of creatine, we observed a nominally significant association of rs1153858 with log-transformed creatine (P=0.031) in LURIC ( Table VI in The second locus associated with homoarginine levels was CPS1 on chromosome 2. CPS1 (EC 6.3.4.16) is the rate-limiting enzyme of the hepatic urea cycle catalyzing the production of carbamoyl phosphate from ammonia, bicarbonate, consuming 2 molecules of ATP. 35 Deficiency of this enzyme results in hyperammonemia, which may be neonatally lethal or become manifest through environmental factors in adulthood. More than 200 mutations in the CPS1 gene have been reported to date. 35 The top SNP in our GWAS, rs7422339, encodes the substitution of asparagine for threonine (T1406N) in a region that is critical for N-acetyl-glutamate binding and results in 20% to 30% higher enzymatic activity. 36 The same variation has been shown to influence nitric oxide metabolite concentrations and vasodilation, 37 the creatinine serum concentration, 38 homocysteine, 39 and it has also been associated with the risk of pulmonary hypertension in newborns. 40 In line with previous publications, the A allele of rs7422339 was associated with lower arginine levels in LURIC (although not significantly), beyond the association with lower homoarginine (Table VI in the online-only Data Supplement). Association with homocysteine was of borderline significance in LURIC with heterozygous individuals having higher levels, whereas there was no association with creatinine (data not shown).
The third locus influencing homoarginine was at 5p13.2 with the nearest gene being AGXT2. The AGXT2 gene encodes the mitochondrial alanine-glyoxylate aminotransferase, which catalyzes the conversion of glyoxylate to glycine using l-alanine as the amino donor, 41 but it also catalyzes the transamination of asymmetrical dimethylarginine to α-keto-δ-(N,N-dimethylguanidino) valeric acid, 42 and overexpression of AGXT2 has been shown to protect from asymmetrical dimethylarginine-induced impairment in nitric oxide production in endothelial cells. 43 Furthermore, a recent GWAS of metabolic traits in human urine identified rs37369 in the coding sequence of AGXT2 to be strongly associated with β-aminoisobutyrate. 44 This polymorphism encodes a nonsynonymous valine-to-isoleucine (V140I) substitution and is a likely candidate to be the causative SNP of hyper-β-aminoisobutyric aciduria. 44 Another recent GWAS confirmed AGXT2 to be an important regulator of methylarginines and suggested that this gene represents a novel mechanism for the regulation of blood pressure through the kidney, with the T allele at rs37369 causing a modest increase in diastolic blood pressure. 45 The same SNP was identified in our GWAS to be associated with serum homoarginine. We did not observe a significant association with blood pressure, although there was a tendency toward higher systolic and diastolic blood pressures in carriers of the T allele (data not shown).
Furthermore, we identified another chromosomal region with a suggestive association to homoarginine serum levels at the MED23/ARG1 locus on chromosome 6. Arginase (ARG1, EC 3.5.3.1) catalyzes the last step of the urea cycle. The isoform encoded by ARG1 contributes 98% of the arginase activity in liver but is also present in red cells. The polymorphisms with suggestive association to homoarginine identified in our study reside in intronic regions of Homo sapiens mediator complex subunit 23 gene (MED23) or ARG1 gene with both transcripts located on different DNA strands and showing a high degree of overlap. There was no linkage to several pathogenic SNPs in the ARG1 gene causing arginase deficiency that have been described previously.
To attempt to replicate the association of SNPs identified in our GWAS with serum homoarginine, we genotyped the lead SNPs in 2 additional cohorts, the 4D study and the GECOH study. The association of rs1153858 at the GATM locus with homoarginine could be replicated in both studies, whereas there was no significant association for rs37370 at the AGXT2 locus. In the 4D study, there was also a significant association of rs1047891 at the CPS1 locus.
Conclusions
In our GWAS, we identified 3 chromosomal regions significantly associated with serum homoarginine and another region with suggestive association. All of these regions harbor genes that are located in the mitochondrium and have been linked to arginine metabolism. The strongest association, which was replicated in both the 4D and GECOH studies, was found for GATM, which synthesizes and catabolizes arginine/homoarginine, whereas CPS1 and ARG1 are involved in the urea cycle and the synthesis of arginine/ homoarginine.
